The National Hemophilia Foundation (NHF) has announced a new two-year pilot program that aims to improve the efficacy of patient infusion logs and reporting through a partnership with Audaire Health, Inc., specialty pharmacies, and hemophilia treatment centers (HTCs).
Audaire Health is providing an easy-to-use data tracking tool that can instantly record infusions, bleeds and other adverse effects to the patient’s care team and specialty pharmacy. NHF hopes that the program will show the benefit of not only patient adherence, but the cost savings associated with an integrated data system that operates at multiple touchpoints along the patient’s care.
Under the program, a pharmacy will dispense factor to the patient with a unique tracking code. After infusion, the patient will only have to scan the code for the information to be sent to the Audaire database where it can be accessed by the pharmacy and the care team.
“The advantages to the patient are multiple,” says Michelle Rice, senior vice president of external affairs at NHF. “It greatly reduces the burden of infusion logging on the patient, while also ensuring greater accuracy of data available to the patient’s care team and payers.”
Insurance companies are increasingly insisting on patient logs from either patients themselves or pharmacies before prescriptions can be filled. The Audaire platform will make it easier for all participants to report on adherence. The care team will also have more accurate data into adverse events and efficacy of treatment regimes.
The Audaire pilot program will engage two specialty pharmacies, BioMatrix Specialty Pharmacy, and one other to be determined and three federally recognized hemophilia treatment centers (HTCs), Cascade Hemophilia Consortium, Henry Ford Hospital Adult Hemophilia and Thrombosis Treatment Center, and Western New York BloodCare. NHF will present initial findings of the program in the fall of 2019.
“NHF believes that following prescribed treatments is a key to lowering costs and improving quality of life for people with bleeding disorders,” said Val D. Bias, CEO of the National Hemophilia Foundation. “We hope this program can make a real difference in people’s lives.”
Source: National Hemophilia Foundation